Shares of CureVac (NASDAQ:CVAC – Get Rating) have earned an average rating of “Hold” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $57.50.
CVAC has been the subject of a number of recent analyst reports. UBS Group cut shares of CureVac from a “neutral” rating to a “sell” rating in a research note on Wednesday, December 22nd. Zacks Investment Research upgraded shares of CureVac from a “sell” rating to a “hold” rating in a research note on Wednesday, March 23rd. Bank of America cut shares of CureVac from a “neutral” rating to an “underperform” rating and cut their target price for the stock from $55.00 to $20.00 in a research note on Friday, January 21st. Finally, JMP Securities began coverage on shares of CureVac in a research note on Tuesday, January 18th. They set an “outperform” rating and a $52.00 target price for the company.
CVAC stock traded down $0.51 during trading hours on Monday, reaching $17.18. The stock had a trading volume of 20,560 shares, compared to its average volume of 634,472. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.61 and a current ratio of 1.79. The stock has a 50-day simple moving average of $17.82 and a 200 day simple moving average of $30.57. CureVac has a fifty-two week low of $14.20 and a fifty-two week high of $130.48.
About CureVac (Get Rating)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza.
- Get a free copy of the StockNews.com research report on CureVac (CVAC)
- 3 Undervalued Stocks The Insiders Are Buying
- The Market For Gamestop Is Near A Turning Point
- PayPal Stock is Still Ready for Bargain Hunting
- It’s Personal: 3 Personal Care Stocks to Own in Volatile Markets
- Conagra Stock Has More Room to Grow
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.